Impact of partial reimbursement on hepatitis B antiviral utilization and adherence

Table 3 Factors associated with good adherence

Parameter	β	OR (95%CI)
Age (yr)
18-45 vs ≤ 18a	-0.3297	0.719 (0.559-0.926)
> 45 vs ≤ 18b	-0.4048	0.667 (0.513-0.867)
Gender (1 = male; 0 = female)	-0.0382	0.963 (0.886-1.046)
Insurance type (1 = medical insurance; 0 = paid out-of-pocket)	0.1200	1.128 (0.987-1.288)
Disease status (1 =; 0 = reference;)b	0.2516	1.286 (1.164-1.422)
Patient status (1 = new patients; 0 = existing patients)	-0.0341	0.966 (0.860-1.086)
Reimbursement implementation (1 = Yes; 0 = No)b	0.1502	1.162 (1.047-1.290)
Insurance type patient statusa	-0.1980	0.820 (0.703-0.957)
Insurance type reimbursement implementationb	0.3518	1.422 (1.220-1.657)

^aP < 0.05;

^bP < 0.01, new vs existing patients. 1 = having one of the following characteristics: (1) serum alanine aminotransferase over two times upper limit of normal; (2) alanine aminotransferase DNA ≥ 20000 IU/mL for hepatitis B e antigen (HBeAg) (+) patients; or (3) HBV DNA ≥ 2000 IU/mL for HBeAg (-) patients.